2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T9de0,

Summary Table

Feature	Type I (Familial Chylomicronemia)	Type IIa (Familial Hypercholesterolemia)	Type IIb (Familial Combined Hyperlipidemia)	Type III (Familial Dysbetalipoproteinemia)	Type IV (Familial Hypertriglyceridemia)	Type V (Mixed)
Risk Factors	Autosomal recessive; presents in childhood	Autosomal dominant; 1 in 250 (heterozygous), 1 in 1 million (homozygous)	Autosomal dominant; most common familial lipid disorder	ApoE2/E2 homozygosity; requires a metabolic trigger (obesity, DM, hypothyroidism)	Autosomal dominant; worsened by alcohol, obesity, estrogen	Combination of genetic susceptibility + secondary triggers
Etiology	Lipoprotein lipase (LPL) deficiency or ApoC-II deficiency	Defective or absent LDL receptors	Overproduction of ApoB-containing lipoproteins (VLDL and LDL)	Defective ApoE leading to impaired clearance of IDL and chylomicron remnants	Hepatic VLDL overproduction	LPL dysfunction + VLDL overproduction
Lipoprotein Elevated	Chylomicrons	LDL	LDL + VLDL	IDL (beta-VLDL)	VLDL	Chylomicrons + VLDL
Lipid Profile	TG severely elevated (>1000); cholesterol normal or mildly elevated	LDL severely elevated; TG normal	Both LDL and TG elevated	Both cholesterol and TG elevated (roughly equal)	TG elevated (250-1000); cholesterol normal or mildly elevated	TG severely elevated (>1000); cholesterol also elevated
Patient Presentation	Recurrent pancreatitis in childhood	Premature atherosclerotic cardiovascular disease (ASCVD); MI in 30s-40s (hetero) or childhood/teens (homo)	Premature ASCVD; variable phenotype	Premature ASCVD + peripheral vascular disease	Usually detected incidentally; pancreatitis if TG >1000	Pancreatitis + ASCVD risk
Classic Physical Exam	Eruptive xanthomas, lipemia retinalis, hepatosplenomegaly	Tendon xanthomas (Achilles, hand extensors), xanthelasma, corneal arcus in young adults	No pathognomonic exam findings	Palmar xanthomas (pathognomonic), tuberoeruptive xanthomas	Eruptive xanthomas if TG very high	Eruptive xanthomas, hepatosplenomegaly
Key Diagnostic Results	Creamy supernatant on refrigerated serum; TG >1000	LDL >190 (adult) or >160 with family history; genetic testing for LDLR mutation	Elevated LDL + TG; family members with variable lipid phenotypes	Broad beta band on lipoprotein electrophoresis; ApoE genotyping (E2/E2)	Elevated VLDL on ultracentrifugation; TG 250-1000	Creamy supernatant + turbid infranatant on refrigerated serum
Management	Extreme fat restriction (<15g/day); no role for statins	High-intensity statin + ezetimibe; PCSK9 inhibitors for refractory cases	Statin + fibrate or niacin	Fibrate as first-line (dramatic response); statin as adjunct	Fibrate first-line; lifestyle modification	Fibrate + extreme dietary restriction; address secondary causes
Keywords	Creamy supernatant, eruptive xanthomas in a child, pancreatitis, LPL deficiency	Tendon xanthomas, corneal arcus in young adult, LDL receptor, MI at age 35, homozygous = childhood MI	Most common familial lipid disorder, variable phenotype in family	Palmar xanthomas, broad beta band, ApoE2, dramatic response to fibrate	Alcohol-triggered hypertriglyceridemia, VLDL overproduction	Creamy top + turbid bottom, combined features of Type I and IV

1. Pathophysiology

Understanding familial dyslipidemias requires a firm grasp of the lipoprotein metabolism pathway. Each type represents a breakdown at a different point in this pathway, and the exam tests whether you can connect the molecular defect to the clinical phenotype.

Normal lipoprotein metabolism in brief: Dietary fat is packaged into chylomicrons by the intestine. In the capillary beds, lipoprotein lipase (LPL) hydrolyzes the triglycerides in chylomicrons and VLDL, releasing free fatty acids to tissues. LPL requires ApoC-II as a cofactor. After triglyceride removal, chylomicrons become chylomicron remnants, which are cleared by the liver via ApoE-mediated receptor binding. The liver independently produces VLDL, which undergoes the same LPL-mediated lipolysis to become IDL, and then LDL. LDL is cleared from the circulation by hepatic LDL receptors that recognize ApoB-100.

Type I (Familial Chylomicronemia): The defect is at the very first step of triglyceride processing. Either LPL itself is absent or dysfunctional, or its essential cofactor ApoC-II is deficient. Without LPL activity, chylomicrons cannot be broken down and accumulate in the plasma. This is why the serum turns grossly lipemic and, when refrigerated overnight, forms a creamy supernatant (chylomicrons float because of their low density). The severe hypertriglyceridemia causes eruptive xanthomas (triglyceride-laden macrophages deposited in the skin) and places the patient at high risk for acute pancreatitis from direct fatty acid toxicity to pancreatic acinar cells. Critically, because the LDL pathway is unaffected, these patients do not develop premature atherosclerosis. The disease presents in childhood, which is unusual for lipid disorders and should immediately raise suspicion.

Type IIa (Familial Hypercholesterolemia, FH): This is the highest-yield familial dyslipidemia on exams. The defect involves the LDL receptor on hepatocytes. More than 1600 mutations have been described, but they all lead to the same outcome: impaired clearance of LDL from the blood. In heterozygous FH, the patient has one functional copy, LDL levels are roughly 2x normal (typically 300-400 mg/dL), and they develop premature ASCVD in their 30s to 50s. In homozygous FH, both copies are defective, LDL levels reach 600-1000+ mg/dL, and patients can suffer MI before age 20. The pathophysiology directly explains the physical exam findings: sustained LDL elevation leads to cholesterol deposition in tendons (tendon xanthomas, especially the Achilles tendon and hand extensor tendons), in the periorbital skin (xanthelasma), and at the corneal periphery (corneal arcus). Tendon xanthomas are considered virtually pathognomonic for FH and should never be dismissed as a background finding in a vignette.

Type IIb (Familial Combined Hyperlipidemia, FCH): This is the most common inherited lipid disorder, affecting roughly 1-2% of the population. The defect is hepatic overproduction of ApoB-100, leading to excess secretion of both VLDL and LDL. The key conceptual point is that this disorder has a variable phenotype, even within the same family: one member might show isolated hypercholesterolemia, another might show isolated hypertriglyceridemia, and a third might show both. This phenotypic variability distinguishes it from FH (where LDL is consistently and markedly elevated). These patients develop premature ASCVD but lack the dramatic physical exam findings seen in FH.

Type III (Familial Dysbetalipoproteinemia): The defect is in ApoE, the ligand that mediates hepatic uptake of chylomicron remnants and IDL. Patients are homozygous for the ApoE2 allele, which binds poorly to hepatic remnant receptors. However, ApoE2/E2 homozygosity alone is usually not sufficient to cause disease. A second metabolic hit (obesity, diabetes mellitus, hypothyroidism, or estrogen deficiency) is typically required to unmask the phenotype. The accumulated IDL particles (also called beta-VLDL) are both cholesterol-rich and triglyceride-rich, producing a characteristic pattern of roughly equal elevation of cholesterol and triglycerides. These abnormal remnant particles are highly atherogenic and are taken up by macrophages in unusual locations, producing palmar xanthomas (yellowish deposits in the palmar creases), which are pathognomonic for this disease. Tuberoeruptive xanthomas over the elbows and knees are also common.

Type IV (Familial Hypertriglyceridemia): The defect is hepatic overproduction of VLDL, resulting in isolated elevation of triglycerides while LDL remains normal. The underlying mechanism is not fully characterized but involves increased hepatic lipogenesis. The clinical significance depends on the degree of elevation: moderate hypertriglyceridemia (250-500) carries a modest increase in ASCVD risk, while severe elevation (>1000) places the patient at risk for pancreatitis. This disorder is strongly modulated by secondary factors such as alcohol intake, uncontrolled diabetes, obesity, and estrogen use. In a vignette, expect a patient with hypertriglyceridemia where the history reveals heavy alcohol use or poorly controlled diabetes as a precipitant.

Type V: This represents a combination of Type I and Type IV physiology. There is both VLDL overproduction and impaired chylomicron clearance, resulting in elevation of both particle types. On refrigerated serum, this produces the classic finding of a creamy supernatant (chylomicrons) overlying a turbid infranatant (excess VLDL). The clinical picture combines features of both: pancreatitis risk from extreme hypertriglyceridemia plus modest ASCVD risk. It typically presents in adulthood, unlike Type I which presents in childhood.

2. Classification and Clinical Manifestation

Fredrickson-Levy-Lees Classification

Type	Elevated Lipoprotein	Cholesterol	Triglycerides	Serum Appearance	Atherosclerosis Risk	Pancreatitis Risk
I	Chylomicrons	Normal/mild increase	Severely elevated (>1000)	Creamy supernatant, clear infranatant	No	High
IIa	LDL	Severely elevated	Normal	Clear	Very high	No
IIb	LDL + VLDL	Elevated	Elevated	Slightly turbid	Very high	Low
III	IDL (beta-VLDL)	Elevated	Elevated (roughly equal to cholesterol)	Turbid	Very high	Moderate
IV	VLDL	Normal/mild increase	Elevated (250-1000)	Turbid, no supernatant	Moderate	Moderate (if TG >1000)
V	Chylomicrons + VLDL	Elevated	Severely elevated (>1000)	Creamy supernatant + turbid infranatant	Moderate	High

Xanthoma Types by Disease

Xanthoma Type	Appearance	Associated Condition	Exam Significance
Tendon xanthomas	Firm nodules on Achilles tendon, hand extensors	Type IIa (FH)	Virtually pathognomonic for FH
Xanthelasma	Yellowish plaques on eyelids	Type IIa (but also nonspecific)	Common but not diagnostic alone
Corneal arcus	White/grey ring at corneal periphery	Type IIa (when present in patient <45 years old)	Nonspecific in elderly; significant when young
Eruptive xanthomas	Small yellow papules on extensor surfaces, buttocks	Type I, IV, V (hypertriglyceridemia)	Indicates TG typically >1000
Palmar xanthomas	Yellow deposits in palmar creases	Type III	Pathognomonic for dysbetalipoproteinemia
Tuberoeruptive xanthomas	Larger nodules over elbows, knees	Type III	Strongly associated with Type III
Tuberous xanthomas	Large, lobulated nodules over pressure points	Type IIa, Type III	Cholesterol deposition

3. Diagnostic Workup

Test	Purpose	Applicable Type(s)	Key Finding
Fasting lipid panel	Best initial test for all types	All	Identifies the lipid abnormality pattern
Refrigerated serum test	Differentiates chylomicron-driven vs. VLDL-driven hypertriglyceridemia	I, IV, V	Creamy top = chylomicrons; turbid bottom = VLDL
Lipoprotein electrophoresis	Confirmatory for Type III	III	Broad beta band (beta-VLDL migration)
ApoE genotyping	Confirmatory for Type III	III	Homozygous ApoE2/E2
LDL receptor genetic testing	Confirmatory for FH	IIa	Identifies LDLR, ApoB, or PCSK9 mutations
LPL activity assay	Confirmatory for Type I	I	Absent or severely reduced LPL activity post-heparin
ApoB levels	Helps distinguish IIb from IIa	IIa vs. IIb	ApoB disproportionately elevated in IIb relative to LDL
Cascade family screening	Standard of care once index case is identified	All (especially IIa)	First-degree relatives tested with fasting lipid panel

The workup begins with a fasting lipid panel in every case. The pattern of abnormalities is the first branch point:

For isolated severe hypercholesterolemia (LDL >190 in an adult, >160 in a child) with normal triglycerides, the working diagnosis is Type IIa (FH). The best initial diagnostic step in a clinical vignette is applying the Dutch Lipid Clinic Network Score or Simon Broome criteria, which integrate LDL level, physical findings (tendon xanthomas), family history of premature ASCVD, and genetic testing. Genetic testing for LDLR, ApoB, or PCSK9 gain-of-function mutations is the most accurate confirmatory test. However, a clinical diagnosis of FH can be made without genetic confirmation if the LDL is >190, tendon xanthomas are present, and there is a first-degree relative with premature coronary disease. The exam frequently uses the "LDL >190 with tendon xanthomas in a young patient" combination as the clinical trigger.

For isolated severe hypertriglyceridemia (TG >1000) in a child, think Type I. The refrigerated serum test (leaving the sample overnight at 4 degrees Celsius) is the best initial discriminating test: a creamy supernatant with a clear infranatant confirms chylomicron excess. The most accurate test is a post-heparin LPL activity assay, where heparin releases LPL from the endothelial surface and its activity is measured directly. Absent or near-absent activity confirms the diagnosis. If LPL activity is normal, measure ApoC-II levels to evaluate for cofactor deficiency.

For combined hypercholesterolemia and hypertriglyceridemia with roughly equal elevation of both, suspect Type III. The best initial clue is the lipid pattern itself combined with palmar xanthomas. The confirmatory test is lipoprotein electrophoresis, which demonstrates a characteristic broad beta band representing the abnormal IDL particles that migrate between the pre-beta (VLDL) and beta (LDL) positions. ApoE genotyping showing homozygous E2/E2 provides definitive genetic confirmation. An important point: the standard Friedewald equation for calculating LDL is unreliable in Type III because it assumes a fixed VLDL cholesterol-to-triglyceride ratio, which does not hold when IDL is accumulating.

For isolated hypertriglyceridemia (TG 250-1000) in an adult, consider Type IV after ruling out secondary causes. The refrigerated serum test shows a uniformly turbid sample without a creamy supernatant (excess VLDL distributes evenly rather than floating). The critical workup step here is to exclude secondary causes: poorly controlled diabetes, hypothyroidism, alcohol excess, medications (thiazides, beta-blockers, estrogens, retinoids, protease inhibitors). If TG remains elevated after addressing secondary causes, the diagnosis of familial hypertriglyceridemia is supported.

For severe hypertriglyceridemia (TG >1000) in an adult presenting with features of both chylomicronemia and VLDL excess, consider Type V. The refrigerated serum test shows a creamy supernatant plus a turbid infranatant, distinguishing it from Type I (clear infranatant) and Type IV (no supernatant).

4. Management and Treatment

Type	First-Line Treatment	Adjunctive Therapy	Lifestyle Modifications	Key Considerations
Type I	Extreme dietary fat restriction (<15 g/day, or 15% of calories)	Medium-chain triglyceride (MCT) oil supplementation	Avoid alcohol; avoid oral estrogen	Statins and fibrates are ineffective (defect is in clearance, not production)
Type IIa (Hetero)	High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)	Ezetimibe 10 mg daily; PCSK9 inhibitors (evolocumab 140 mg q2wk or alirocumab 75-150 mg q2wk)	Low saturated fat diet, exercise	Target LDL reduction of at least 50%; consider PCSK9i if LDL remains >70 on max statin + ezetimibe
Type IIa (Homo)	Max-dose statin + ezetimibe + PCSK9 inhibitor	LDL apheresis every 1-2 weeks; lomitapide (MTP inhibitor); evinacumab (anti-ANGPTL3)	Same as above	Most patients require LDL apheresis; liver transplant considered for complete receptor-negative cases
Type IIb	Statin as backbone	Add fibrate (fenofibrate preferred) or niacin for residual TG elevation	Weight loss, reduce refined carbs, limit alcohol	Avoid gemfibrozil + statin combination (myopathy risk); fenofibrate is safer with statins
Type III	Fibrate first-line (fenofibrate 145 mg or gemfibrozil 600 mg BID)	Statin as add-on if needed	Correct the secondary trigger (weight loss, glycemic control, treat hypothyroidism)	Dramatic and rapid response to fibrates is a hallmark; this distinguishes Type III therapeutically
Type IV	Fibrate first-line for TG >500; lifestyle for TG <500	Omega-3 fatty acids (icosapent ethyl 2g BID); niacin	Alcohol cessation, weight loss, glycemic control, reduce refined carbs	If TG >1000, acute pancreatitis prevention takes priority over ASCVD risk reduction
Type V	Extreme dietary fat restriction + fibrate	Address all secondary triggers	Same as Type IV	Very high pancreatitis risk; may require hospitalization for severe cases

Management of Type IIa (FH) deserves the most detailed discussion because it is the most commonly tested.

For heterozygous FH, the cornerstone is a high-intensity statin. Atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily should be initiated at the time of diagnosis, regardless of age (treatment begins in childhood for FH, typically at age 8-10). The goal is at least a 50% reduction in LDL from baseline. If the target is not reached with maximal statin therapy, add ezetimibe 10 mg daily, which blocks intestinal cholesterol absorption via the NPC1L1 transporter and provides an additional 15-20% LDL reduction. If LDL remains above goal despite statin + ezetimibe, PCSK9 inhibitors are indicated. Evolocumab (140 mg subcutaneously every 2 weeks) and alirocumab (75 mg subcutaneously every 2 weeks, up-titrated to 150 mg) work by preventing degradation of LDL receptors on the hepatocyte surface, thereby increasing LDL clearance. These agents can lower LDL by an additional 50-60%.

For homozygous FH, standard pharmacotherapy is often insufficient because there are few or no functional LDL receptors for PCSK9 inhibitors to upregulate. These patients typically require LDL apheresis (an extracorporeal procedure that physically removes LDL particles from the blood) performed every 1-2 weeks. Lomitapide (a microsomal triglyceride transfer protein inhibitor, 5-60 mg daily) reduces hepatic VLDL production and consequently LDL formation, but carries a risk of hepatic steatosis and requires monitoring of liver enzymes. Evinacumab (anti-ANGPTL3 monoclonal antibody, 15 mg/kg IV monthly) is a newer agent that lowers LDL through an LDL-receptor-independent pathway, making it effective even in receptor-negative homozygous FH. Liver transplantation is a last resort for receptor-negative patients unresponsive to all other therapies, as the transplanted liver provides functional LDL receptors.

For Type III, the management pearl is the dramatic response to fibrate therapy. Because the underlying defect is impaired remnant clearance (not production), fibrates, which activate PPAR-alpha and enhance LPL activity and remnant clearance, are exceptionally effective. Patients often see normalization of lipids within weeks. However, addressing the secondary metabolic trigger (weight loss for obesity, metformin for diabetes, levothyroxine for hypothyroidism) is equally important and may even resolve the dyslipidemia on its own.

For hypertriglyceridemia (Types IV, V, and the acute management of Type I), the immediate clinical priority depends on the TG level. When TG is >1000 mg/dL, the primary concern is pancreatitis prevention, and the approach centers on extreme fat restriction, IV fluids, and in severe cases, insulin infusion (which activates LPL and accelerates triglyceride clearance). Once the acute risk is mitigated, chronic management involves fibrates, omega-3 fatty acids (icosapent ethyl, which has demonstrated ASCVD benefit in the REDUCE-IT trial at 4g/day), and rigorous control of secondary factors. When TG is 500-1000, fibrate therapy is indicated. When TG is <500, lifestyle modification and statin therapy (for overall ASCVD risk) are generally sufficient, with the addition of icosapent ethyl if ASCVD risk is elevated.

Contraindications and drug interactions to remember: Gemfibrozil combined with statins substantially increases the risk of rhabdomyolysis (gemfibrozil inhibits statin glucuronidation). If a fibrate-statin combination is needed, fenofibrate is the safer choice. Statins are contraindicated in pregnancy (Category X) due to teratogenicity. Niacin can worsen glucose tolerance and precipitate gout (via hyperuricemia), making it a poor choice in diabetic or gout-prone patients.

5. Differential Diagnosis and Distractors

Differential	Why It Is Confusing	Key Discriminator
Secondary hyperlipidemia (hypothyroidism, nephrotic syndrome, diabetes, alcohol, medications) vs. any familial type	Both produce abnormal lipid panels; vignettes may include subtle hints of a secondary cause	Check TSH, glucose, urinalysis for protein, medication list, and alcohol history before labeling a lipid disorder as familial. A family history of similar lipid abnormalities and onset at a young age favor a primary/familial cause.
Type IIa (FH) vs. Polygenic hypercholesterolemia	Both present with elevated LDL	FH has tendon xanthomas, LDL >190, autosomal dominant family pedigree, and onset in childhood or young adulthood. Polygenic hypercholesterolemia has a more modest LDL elevation (usually 160-190), no tendon xanthomas, and no clear Mendelian inheritance.
Type IIa vs. Type IIb	Both have elevated LDL and premature ASCVD	Type IIa has normal triglycerides and consistent hypercholesterolemia across affected family members. Type IIb has elevated triglycerides as well, and family members show variable phenotypes (some with high cholesterol alone, some with high TG alone, some with both).
Type III vs. Type IIb	Both show combined elevation of cholesterol and triglycerides	Type III has palmar xanthomas (pathognomonic), roughly equal cholesterol and TG levels, and a broad beta band on electrophoresis. Type IIb lacks palmar xanthomas and does not show the broad beta band.
Type I vs. Type V	Both have severely elevated TG, eruptive xanthomas, and pancreatitis risk	Type I presents in childhood with a clear infranatant on refrigerated serum. Type V presents in adulthood with a turbid infranatant (indicating VLDL excess in addition to chylomicrons).
Type IV vs. secondary hypertriglyceridemia from alcohol	Both show isolated TG elevation	Familial Type IV persists after alcohol cessation and has a positive family history. Alcohol-induced hypertriglyceridemia resolves with abstinence. The vignette will either include or exclude ongoing alcohol use as the discriminating detail.
FH vs. Sitosterolemia	Both present with tendon xanthomas and severely elevated "cholesterol" in childhood	In sitosterolemia, the elevated sterols are plant sterols (phytosterols), not cholesterol. Standard lipid panels may overestimate LDL. A plant sterol level distinguishes the two. Sitosterolemia responds to ezetimibe but not to statins.
Acute pancreatitis from hypertriglyceridemia vs. other pancreatitis causes	Vignette presents pancreatitis and the student focuses on gallstones or alcohol	If TG >1000 mg/dL is present, it is the most likely etiology of pancreatitis regardless of other risk factors mentioned. The lipid level itself is the key vignette detail.

6. Traps and High-Yield Pearls

The most common trap with familial dyslipidemia questions is failing to distinguish primary from secondary causes. A vignette might describe a patient with elevated LDL and then bury a TSH of 12 mU/L or a urine dipstick showing 4+ protein in the history. Students who jump straight to "familial hypercholesterolemia" without checking for hypothyroidism or nephrotic syndrome will select the wrong diagnosis. The exam tests whether you systematically exclude secondary causes before invoking a genetic disorder.

The second major trap involves Type III dysbetalipoproteinemia. Test-writers love this condition because it has two pathognomonic features that most students do not know: palmar xanthomas and the broad beta band on electrophoresis. A vignette describing yellow discoloration in the palmar creases of a middle-aged patient with combined hyperlipidemia is pointing directly at Type III, but students who are unfamiliar with palmar xanthomas will incorrectly select Type IIb.

A third trap is the management of homozygous FH. Students instinctively choose "high-dose statin" for any hypercholesterolemia question. However, in homozygous FH with complete absence of LDL receptors, statins have minimal effect because they work by upregulating LDL receptor expression on hepatocytes. The correct answer in a vignette describing a child with LDL >600 and a family history of childhood MI is LDL apheresis, not statins alone. PCSK9 inhibitors similarly have reduced efficacy in receptor-negative homozygous FH, which is why evinacumab (receptor-independent mechanism) was developed.

Fourth, the refrigerated serum test is a classic exam concept. Students should be able to match each pattern to the correct type: creamy top with clear bottom = Type I, uniformly turbid = Type IV, creamy top with turbid bottom = Type V. This simple test appears repeatedly in the question pool.

Finally, remember that Type I does not cause atherosclerosis. This is counterintuitive, since the lipid levels are severely abnormal. The reason is that chylomicrons are too large to penetrate the arterial intima. The atherogenic particles are LDL and IDL, not chylomicrons. A question asking about ASCVD risk in a child with recurrent pancreatitis and eruptive xanthomas is testing whether you know that the answer is "no increased atherosclerosis risk" despite the dramatic lipid panel.

The core competency being tested across all familial dyslipidemia questions is pattern recognition: linking the lipoprotein class elevated to the molecular defect, the physical exam findings, and the correct treatment. The Fredrickson classification is the organizing framework, and each type has at least one distinguishing feature that the exam expects you to recall instantly.

1e:["$","$L2d",null,{"article":{"id":"b5e62420-dad2-4a54-8744-396430f39d4a","title":"Hiperkolesterolemia Familial","content":"$2e","category":"Endokrin-Metabolik","created_at":"2026-05-20T17:29:21.725654+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]